Fresh findings showing that the GLP-1 agonist semaglutide extended lifespan in animal models by 12 percent have sparked intense debate over whether metabolic drugs could become mainstream longevity therapies. Longevity experts note that while GLP-1 medications dramatically reduce the risks of cardiovascular disease, diabetes, and systemic inflammation—helping more people reach older age in good health—biological aging constraints mean they are unlikely to push maximum human lifespan limits. Clinicians emphasize that upcoming human trials must determine whether molecular improvements seen with GLP-1 drugs translate into sustained physical resilience and cognitive sharpness in later decades.
About the Author
